Lexicon Pharmaceuticals, Inc. (LXRX)
Lexicon Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of new drugs, particularly in the areas of metabolic, autoimmune, and other serious diseases. Founded in 1995 and headquartered in The Woodlands, Texas, the company utilizes its proprietary gene knockout technology to identify potential drug targets and develop innovative therapies.
Company News
Lexicon Pharmaceuticals submitted additional clinical data to the FDA for Zynquista®, an oral SGLT1/SGLT2 inhibitor for type 1 diabetes, following a complete response letter in December 2024. The FDA requires more time to review the data and will provide feedback in Q4 2025.
U.S. stock futures fell on Monday after three consecutive days of decline. Goldman Sachs has increased its U.S. recession probability from 20% to 35% and warned that the risk of further market correction is still looming.
We have narrowed our search to five small-cap biotech stocks with strong potential for the rest of 2024. These are: ARQT, BCYC, CSTL, PRME, LXRX.
If a trio of Wall Street analysts is correct, three lesser-known stocks could skyrocket in the new year.
Penny stocks to buy according to insiders. The post 3 Top Penny Stocks to Buy According To Insiders In October appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.